RESUMEN
Selective attention to 1 of 2 overlapping objects was assessed in a cuing paradigm. Participants detected or identified targets that appeared in 1 of 6 possible target locations (3 on each object). Significant cuing effects for the simple detection of such targets using both reaction time and sensitivity measures of performance were found. Cuing effects were consistently greater when the participants were required to identify some aspect of the target even when the tasks (detection vs. identification) were equated for overall performance level. These differences in cuing effects between tasks were much reduced if the target locations were no longer grouped into 2 objects. It is suggested that identical stimuli can elicit differing attentional mechanisms depending on task type (rather than task difficulty) and that these mechanisms differ in the nature of the representation of the visual world.
Asunto(s)
Atención , Señales (Psicología) , Discriminación en Psicología , Reconocimiento Visual de Modelos , Detección de Señal Psicológica , Adulto , Análisis de Varianza , Femenino , Humanos , Masculino , Desempeño Psicomotor , Tiempo de ReacciónRESUMEN
In an array of elements whose colors vary can we selectively choose to process all the items of a particular color preferentially in relation to those of another color? We addressed this question by presenting subjects with arrays containing many elements, and recording reaction times to a luminance change of one of the elements. Half the elements had one color and the other half another color--the spatial distribution being random. In two tasks--a simple detection of this change or a choice reaction time to the polarity of the change--we found that reaction times were independent of the number of items in the array. Cuing the subjects as to the color of the target item had no significant influence on the detection task, but subjects were faster if cued for the discrimination task. A further experiment replicated these findings and examined possible costs and benefits. Our final experiment separated the roles of attentional guidance and postattentional processes by having subjects judge the orientation of the target element and varying the magnitude of the target flash that defined which element was the target. We found that this judgment was also affected by color cuing, and that the size of the effect interacted with the flash strength, suggesting that color cuing has its influence at the stage of attentional guidance. We conclude that subjects can selectively attend to items on the basis of color given the appropriate task and stimulus dynamics.
Asunto(s)
Atención/fisiología , Percepción de Color/fisiología , Señales (Psicología) , Electrofisiología , Fijación Ocular/fisiología , Humanos , Tiempo de ReacciónRESUMEN
PURPOSE: Sampling error is an inherent problem of prostate biopsy, and the determination of clinical significance based on biopsy results is problematic. We quantify the dimensions of these problems by computer simulation. MATERIALS AND METHODS: We constructed 3-dimensional solid computer models of 59 autopsy prostates containing clinically undetected prostate cancer, and performed simulations of the standard prostate biopsy method. RESULTS: Biopsy simulation detected 19 tumors from the 59 prostates, the majority of which were in the most accessible portion of the prostate, the posterior peripheral zone. Using 0.5 cc or greater tumor volume or less than 0.5 cc and Gleason sum 7 or greater as criteria of significance, the model detected 58% (11 of 19) significant tumors and 20% (8 of 40) insignificant tumors. With 0.25 cc or greater tumor volume or less than 0.25 cc and Gleason sum 7 or greater as criteria 15 of 29 significant (52%) and 4 of 30 insignificant (13%) tumors were detected. Among significant tumors defined by either volume criterion there was a statistical difference between detected and undetected tumors in terms of mean tumor volume and mean ratio of tumor volume-to-prostate volume. Among insignificant tumors defined by either criterion there was no such difference. CONCLUSIONS: As much as 20 to 40% of currently detected prostate cancer may be histologically insignificant, as 4 of 19 cancers were detected when 0.25 cc was used as volume determinant of clinical significance and 8 of 19 were detected when 0.5 cc volume was used. These tumors are detected randomly. On the other hand, perhaps only one-half to three-fourths of clinically significant prostate cancers are being detected, and then only because the volume and anatomic location make them hard to miss.
Asunto(s)
Simulación por Computador , Próstata/patología , Neoplasias de la Próstata/patología , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Reacciones Falso Negativas , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Clinically benign, whole untrimmed prostates were obtained from 104 patients at autopsy, completely sectioned, and examined microscopically. The histological and gross findings of the prostate were correlated with premortem prostatic acid phosphatase levels (PAP, enzymatic method, ACA, Dupont Co.) to determine how often carcinoma of the prostate (CAP) affected PAP levels and to identify other findings within the prostate associated with elevated PAP levels. Sixty (58%) prostates did not have CAP, 34 (33%) had CAP smaller than 1 ml in volume, and 10 (10%) had CAP larger than 1 ml in volume. PAP levels were elevated (greater than 1 U/L) in 8 of 60 (13%) prostates without CAP, in 2 of the 34 (6%) prostates with CAP smaller than 1 ml, and in 1 of the 10 (10%) prostates with CAP larger than 1 ml. These differences were not statistically significant. Likewise, a statistically significant correlation between PAP levels and patient age, patient race, severe inflammation, of high grade prostatic intraepithelial neoplasia (PIN) was not found. However, there was a statistically significant correlation between PAP levels and prostate weight (p < 0.0001). This study suggest that PAP cannot distinguish between patients with clinically undetected CAP and patients without CAP. Furthermore, elevated PAP levels are often not due to metastatic CAP and additional evidence should be present, even in patients with known CAP, before an elevated PAP level is considered to be conclusive evidence of metastatic CAP.
Asunto(s)
Fosfatasa Ácida/análisis , Próstata/enzimología , Neoplasias de la Próstata/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Autopsia , Diagnóstico Diferencial , Humanos , Hiperplasia , Masculino , Persona de Mediana Edad , Tamaño de los Órganos , Valor Predictivo de las Pruebas , Próstata/anatomía & histología , Próstata/patología , Neoplasias de la Próstata/enzimologíaRESUMEN
OBJECTIVE: To evaluate serum prostate-specific antigen (PSA) levels in patients with granulomatous prostatitis, an inflammatory condition that can clinically mimic malignancy. PATIENTS AND METHODS: The study comprised 10 consecutive patients (age range 53-80 years) with histologically-documented granulomatous prostatitis and who had serum PSA levels recorded before and after diagnosis. RESULTS: PSA levels in six of the patients were normal (< 4.0 ng/mL) at diagnosis. The other four had slightly elevated PSA levels, with three being between 4.0 and 6.0 ng/mL and the other 10.1 ng/mL. In six of the patients, there was a dramatic decrease (> 40%) in PSA level within 6-12 months after the histological documentation of granulomatous prostatitis. At the final follow-up, all 10 patients had normal PSA levels. CONCLUSION: Granulomatous prostatitis may cause a relatively mild and transient increase in serum PSA level which resolves when the inflammation subsides.
Asunto(s)
Granuloma/sangre , Antígeno Prostático Específico/sangre , Prostatitis/sangre , Anciano , Anciano de 80 o más Años , Granuloma/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Prostatitis/diagnósticoRESUMEN
Carcinoma of the prostate (CAP) is often graded as well, moderately or poorly differentiated. We identified 74 well differentiated stage A1 CAP, 58 stage D1 CAP with moderately differentiated metastases, 107 moderately differentiated stage D2 CAP, and 53 poorly differentiated stage D2 CAP and divided each group into 3, 4 or 5 histological patterns. We found that each histological pattern within well, moderately and poorly differentiated prostate carcinoma had similar survival rates. These observations suggest that, using Light microscopy, 3 prognostically significant grades of CAP can be identified - well, moderately and poorly differentiated.
RESUMEN
OBJECTIVE: To determine how many latent prostate gland carcinomas (unsuspected carcinomas in clinically benign prostate glands) metastasize. DESIGN: The prostate glands and the pelvic and paraaortic lymph nodes were removed at autopsy from 209 consecutive patients with clinically benign prostate glands. The prostate glands were completely sectioned and examined microscopically using full cross sections. Pelvic and para-aortic lymph nodes were identified and examined microscopically for metastases. RESULTS: Seventy-nine (38%) of the prostate glands had latent prostate carcinomas. None of the pelvic or paraaortic lymph nodes contained metastases. CONCLUSION: This study suggests that few latent prostate-gland carcinomas metastasize.
Asunto(s)
Carcinoma/patología , Metástasis de la Neoplasia , Neoplasias de la Próstata/patología , Anciano , Anciano de 80 o más Años , Aorta , Cadáver , Humanos , Ganglios Linfáticos/patología , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Pelvis , Próstata/patologíaRESUMEN
OBJECTIVES: To compare the traditional normal range (TNR) of 0.0 to 4.0 ng/mL for serum prostate-specific antigen (PSA) to age-specific normal ranges (ASNRs). METHODS: An autopsy series of completely sectioned, clinically benign prostates from 171 consecutive Caucasian men over the age of 40 years was selected. These patients were divided into those having no prostate cancer at autopsy, prostate cancer less than 1 cc in volume, and prostate cancer at least 1 cc in volume. The PSA values of each group were compared using both the TNR and the ASNR. RESULTS: Twenty-three of 105 (21.9%) patients with no cancer had elevated PSA values by the TNR, whereas only 18 (17.1%) were elevated using the ASNR. Nine of 54 (16.7%) with cancer less than 1 cc were elevated using the TNR, and 7 of 54 (13.0%) using the ASNR. Of 12 patients with cancer at least 1 cc, all had elevated PSA levels using the TNR and 11 (91.7%) were elevated using the ASNR. All discrepancies between the TNR and ASNR occurred in the 60- to 79-year age range. CONCLUSIONS: Use of ASNRs appears helpful in increasing the specificity of PSA by eliminating some elevated values in patients in their 60s and 70s.
Asunto(s)
Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/sangre , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Humanos , Masculino , Persona de Mediana Edad , Valores de ReferenciaRESUMEN
OBJECTIVES: To determine whether human prostatic carcinoma cells express Class I and/or Class II major histocompatibility complex (MHC) determinants and whether they might thus be immune-competent targets for cell-mediated cytotoxicity. MATERIALS AND METHODS: Immunohistochemistry, performed both before and after neuraminidase digestion, was employed to compare 13 benign prostatic hyperplasias with 42 primary and 44 metastatic prostatic carcinomas obtained from the United Kingdom and from the United States of America. Expression of beta 2-microglobulin was used as the marker of Class I and HLA-DR as the marker of Class II expression. RESULTS: Before desialylation, Class I MHC determinants were expressed in all of the benign hyperplasias, in 26% of primary carcinomas and in 14% of lymph node metastases. Cells expressing Class II determinants were identified in 69% of benign hyperplasias and in 2% of primary carcinomas, but in none of the lymph node metastases. After desialylation. Class I determinants were expressed in 100% of benign hyperplasias. 59% of primary carcinomas and 34% of the lymph node metastases. Class II determinants were expressed in 100% of benign hyperplasias, but only 19% of primary carcinomas and 5% of the lymph node metastases. While more than 50% of epithelial cells in each of the benign hyperplasias expressed MHCs, < 5% of the tumour cell populations in the positive malignant tissues (primary and metastatic) expressed MHCs, even after neuraminidase digestion. No correlation was found between expression of Class I or Class II MHC and Gleason morphological grade. CONCLUSIONS: Failure to express Class I and/or Class II MHC determinants is a common feature of the majority of human prostatic carcinoma cells. Absence of these recognition molecules may be associated with avoidance of immune-surveillance and contribute to the metastatic dissemination of this malignancy.
Asunto(s)
Antígenos de Histocompatibilidad Clase II/análisis , Antígenos de Histocompatibilidad Clase I/análisis , Próstata/inmunología , Hiperplasia Prostática/inmunología , Neoplasias de la Próstata/inmunología , Epitelio/inmunología , Antígenos HLA-DR/metabolismo , Humanos , Inmunohistoquímica , Metástasis Linfática/inmunología , Masculino , Microglobulina beta-2/metabolismoRESUMEN
BACKGROUND: It is unknown how often prostate carcinomas are diagnosed as a result of urinary obstructive symptoms or whether prostate carcinomas diagnosed because of obstructive symptoms have a favorable or unfavorable prognosis. It is also unknown whether racial differences in obstructive symptoms could help explain why black men with prostate carcinoma are diagnosed with more advanced stages and grades of prostate carcinoma than are white men with prostate carcinoma. METHOD: At a single Veterans Administration Medical Center, 478 consecutive cases of prostate carcinoma diagnosed between 1973 and 1985 were identified. The incidence of obstructive symptoms at diagnosis, racial differences in obstructive symptoms, and the survival of patients with and without obstructive symptoms, stratified by stage and grade, were determined. In addition, racial differences in the frequency of surgical intervention required to relieve the obstructive symptoms were determined. RESULTS: All patients diagnosed with Stage A prostate carcinoma and most (82%) patients diagnosed with Stage C prostate carcinoma had obstructive symptoms. Those diagnosed with Stage B and Stage D prostate carcinomas had with similar frequencies (53% and 55%, respectively) of obstructive symptoms. Survival, stratified by stage and grade, was similar for men with and without obstructive symptoms. The incidences of obstructive symptoms and the frequency of surgical intervention to relieve the obstructive symptoms, stage for stage, were similar for white and black men. CONCLUSION: Survival, stratified by stage and grade, is not affected adversely by obstructive symptoms. Neither racial differences in the incidence of obstructive symptoms nor the frequency with which obstructive symptoms require surgical correction explain why black men with CAP consistently are diagnosed more frequently with Stage D prostate carcinoma and less frequently with Stage A CAP than white men with CAP.
Asunto(s)
Población Negra , Carcinoma/complicaciones , Carcinoma/diagnóstico , Neoplasias de la Próstata/complicaciones , Neoplasias de la Próstata/diagnóstico , Obstrucción Uretral/diagnóstico , Obstrucción Uretral/etiología , Población Blanca , Adulto , Negro o Afroamericano , Anciano , Anciano de 80 o más Años , Carcinoma/patología , Carcinoma/cirugía , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Prostatectomía , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/cirugía , Tasa de Supervivencia , Obstrucción Uretral/patología , Obstrucción Uretral/cirugíaRESUMEN
OBJECTIVES: To determine how prostatic infarcts affect serum prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) levels. METHODS: Two hundred eighteen clinically benign, whole prostates were obtained at autopsy, completely sectioned, and examined histologically. PSA and PAP levels were determined from premortem serum. RESULTS: Six of the 218 (2.8%) prostates had infarcts. The infarcts were usually multiple and usually located in the central and/or middle concentric zones of the middle third of the prostate without a preference for a particular lobe. Serum PSA by immunoradiometric assay were elevated in all 6 cases. Serum PAP by both enzymatic assay (ACA), and immunoradiometric assay were available for 5 cases and were elevated by both methods in 2 cases, approached elevated levels by both methods in 1 case, and were normal by both methods in 2 cases. The PSA and PAP levels appeared to be affected more by the age than by the size of the infarct. CONCLUSIONS: Prostatic infarcts elevate PSA levels more frequently than PAP levels, and prostatic infarcts may be responsible for some unexplained elevations of serum PSA and PAP levels.
Asunto(s)
Fosfatasa Ácida/sangre , Infarto/sangre , Antígeno Prostático Específico/sangre , Próstata/irrigación sanguínea , Anciano , Humanos , Infarto/etiología , Infarto/patología , Masculino , Persona de Mediana EdadRESUMEN
Between 1972 and 1986, 134 patients with stage A carcinoma of the prostate (CAP) were diagnosed at a single Veterans Administration medical centre and followed annually by the hospital tumour registry. Seventy-four were classified as stage A1, defined as non-palpable, well-differentiated CAP, regardless of amount, found unexpectedly on transurethral resection of the prostate (TURP). Twenty-eight were classified as stage A2, defined as non-palpable, moderately or poorly differentiated CAP, regardless of amount, found unexpectedly on TURP. The remaining 32 were reclassified as atypical hyperplasia/adenosis (AH/A) rather than CAP. The survival of each group was compared with the survival of a control group from the same medical centre who had TURPs showing histologically proven benign prostatic hyperplasia (BPH). Survival and tumour progression were similar for patients with stage A1 CAP, AH/A and BPH. Furthermore, patients with stage A1 CAP, with or without therapy, had similar survivals as patients with BPH in each age group (under 65, 65-74 and over 74 years). Stage A2 CAP was associated with a significantly worse survival and more tumour progression. Within stage A1 CAP and stage A2 CAP the percentage of chips with CAP or the amount of CAP removed did not affect survival.
Asunto(s)
Enfermedades de la Próstata/mortalidad , Hiperplasia Prostática/mortalidad , Neoplasias de la Próstata/mortalidad , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Modelos de Riesgos Proporcionales , Enfermedades de la Próstata/complicaciones , Enfermedades de la Próstata/patología , Hiperplasia Prostática/complicaciones , Hiperplasia Prostática/patología , Neoplasias de la Próstata/complicaciones , Neoplasias de la Próstata/patología , Análisis de Supervivencia , Factores de TiempoRESUMEN
Quantitation of serum prostate-specific antigen (PSA) has recently come into widespread use. Controversy exists regarding its usage in screening for carcinoma of the prostate (CAP), based partly on concern that it may detect small foci of CAP that will not cause any significant morbidity or mortality. This study was conducted to evaluate serum PSA levels in stage A1 CAP. The authors identified 143 consecutive men who had PSA levels drawn within 8 weeks of transurethral resection performed for presumed benign prostatic hyperplasia. One hundred twenty-four of these (86.7%) had no cancer, 11 (7.7%) were found to have stage A1 CAP, and eight (5.6%) were found to have CAP beyond stage A1. The mean PSA level in patients with stage A1 CAP was 2.3 ng/mL, and the benign (no cancer) group had a mean PSA level of 3.8 ng/mL. Ten of the 11 patients in the stage A1 group had PSA values less than 4.0 ng/mL. Therefore, it was found that most patients with stage A1 CAP did not have elevated PSA levels. In the authors' experience, elevation of PSA levels caused by CAP is indicative of a tumor burden greater than that found in stage A1 CAP.
Asunto(s)
Carcinoma/sangre , Antígeno Prostático Específico/análisis , Neoplasias de la Próstata/sangre , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma/patología , Carcinoma/cirugía , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/cirugíaRESUMEN
BACKGROUND: Black men are known to have a higher incidence and mortality from prostate carcinoma than white men and are more likely to have a more advanced stage or grade of disease diagnosed. METHODS: In a Veterans Administration Medical Center where black and white men have the same eligibility for medical care, the authors reviewed the stage at presentation of 861 consecutive cases of prostate carcinoma diagnosed from 1969-1990. In addition, survival, stratified by race, stage, and grade, was determined on all men in whom prostate cancer was diagnosed from 1969-1985 (525 patients). RESULTS: It was found that 26% of white and 52% of black men with prostate carcinoma presented with Stage D disease. Similar proportions of white and black men with prostate carcinoma presented with Stage D disease between 1969-73 as between 1986-90. The overall survival was poorer for black men because of their higher proportion of Stage D disease, but stratified for grade and stage, survival was similar in both races. CONCLUSIONS: This study suggests that factors other than eligibility for medical care may be responsible for the higher proportion of black men with prostate carcinoma presenting with Stage D prostate carcinoma.
Asunto(s)
Negro o Afroamericano , Neoplasias de la Próstata/mortalidad , Neoplasias de la Próstata/patología , Población Blanca , Anciano , Humanos , Masculino , Estadificación de Neoplasias , Pronóstico , Análisis de Supervivencia , Estados Unidos/epidemiología , VeteranosRESUMEN
Prostate carcinomas begin as well-differentiated lesions. Before metastases occur these carcinomas dedifferentiate into moderately or poorly differentiated lesions and increase in size to at least 1 cm3. Well-differentiated lesions rarely metastasize and metastases are rarely well differentiated. Positive staging lymphadenectomies usually contain moderately differentiated metastases. Patients with moderately differentiated metastases have a statistically significant better survival than patients with poorly differentiated metastases. Metastases typically disseminate as they dedifferentiate, with stage D1 metastases being moderately differentiated and stage D2 metastases being poorly differentiated. "Prostate-specific" immunohistochemical techniques and serum prostate-specific antigen levels may be helpful in determining whether a particular metastases is from the prostate. However, metastases of uncertain origin should rarely, if ever, be attributed to the prostate without confirmation that the patient has a prostate carcinoma with histologic features capable of metastasizing.
Asunto(s)
Adenocarcinoma/patología , Adenocarcinoma/secundario , Neoplasias de la Próstata/patología , Humanos , MasculinoRESUMEN
Transrectal ultrasound detection of prostatic adenocarcinoma was correlated to 63 histological whole mount step sectioned prostatic specimens harvested from 148 consecutive autopsies at our institutions. No patient had known or palpably suspected prostatic adenocarcinoma on premortem digital rectal examination. Prostate specific antigen (PSA) was assayed in each case from premortem serum samples. Of 19 cancers 6 (32%) were detected by transrectal ultrasound and all were hypoechoic. Of the 13 nondetected cancers 7 were isoechoic, 3 were mixed hypoisoechoic, 2 were hypoechoic and 1 was mixed hyperisoechoic. PSA greater than 4 ng./ml. would have aided in cancer detection by suggesting the need for biopsy or further biopsy in 5 cancers with significant volume, which were missed by transrectal ultrasound. The sensitivity (32%) and specificity (64%) of transrectal ultrasound appear too low for use in clinical screening for prostatic adenocarcinoma. PSA and transrectal ultrasound together appear more effective than sonography alone in prostatic adenocarcinoma detection in this series.
Asunto(s)
Adenocarcinoma/diagnóstico por imagen , Neoplasias de la Próstata/diagnóstico por imagen , Adenocarcinoma/patología , Adulto , Anciano , Anciano de 80 o más Años , Autopsia , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de la Próstata/patología , Recto , Sensibilidad y Especificidad , Ultrasonografía/métodosRESUMEN
A small ulcer produced in vitro by monopolar electrocoagulation on endoscopically obtained human antral biopsies and incubated in Trowel T-8 medium at 37 degrees C for 8 h has many histologic features of chronic gastric ulcer in man. Zinc sulfate and acetylcysteine in low concentrations had a significant healing effect in this ulcer model. Since the beneficial effect of zinc sulfate and acetylcysteine was counteracted by N-ethylmaleimide, a known blocker of sulfhydryl compounds, the beneficial effect of these two compounds probably was mediated through sulfhydryl compounds. Using special stain, N-(4-aminophenyl)maleimide, the sulfhydryl groups were localized in the epithelial cells of the surface layer and gastric glands.
Asunto(s)
Acetilcisteína/farmacología , Mucosa Gástrica/efectos de los fármacos , Úlcera Gástrica/tratamiento farmacológico , Sulfatos/farmacología , Compuestos de Sulfhidrilo/fisiología , Zinc/farmacología , Biopsia , Técnicas de Cultivo , Mucosa Gástrica/patología , Humanos , Úlcera Gástrica/patología , Sulfato de ZincRESUMEN
Clinically benign whole, untrimmed prostates and pelvic lymph nodes were obtained from 105 patients at autopsy. All 105 patients had premortem serum from which prostate-specific antigen (PSA) levels were obtained. Sixty-eight did not have carcinoma of the prostate (CAP), 28 had CAP less than 1 ml and 9 had CAP larger than 1 ml. Eleven untrimmed prostates weighed 80 g or more and eight had elevated PSA levels (more than 4.0 ng/ml): five of eight without CAP, two of two with CAP less than 1 ml, and one of one with CAP larger than 1 ml. Ninety-four whole untrimmed prostates weighed less than 80 g and 20 had elevated PSA levels: ten of 60 without CAP, two of 26 with CAP less than 1 ml, and eight of eight with CAP larger than 1 ml. This study suggests that PSA levels from patients with untrimmed prostates weighing 80 g or more (equivalent to a 60-g trimmed prostate) are usually elevated regardless whether CAP is present. However, CAP less than 1 ml, in untrimmed prostates less than 80 g, usually does not elevate PSA levels whereas CAP larger than 1 ml usually does (P less than 0.0001). The likelihood that elevated PSA levels, from patients with untrimmed prostates less than 80 g, are due to CAP larger than 1 ml increases as the PSA level increases.
Asunto(s)
Antígenos de Neoplasias/sangre , Próstata/inmunología , Neoplasias de la Próstata/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Autopsia , Humanos , Masculino , Persona de Mediana Edad , Tamaño de los Órganos , Próstata/anatomía & histología , Antígeno Prostático Específico , Neoplasias de la Próstata/patología , Prostatitis/inmunología , Estadística como AsuntoRESUMEN
Eighty-two of 307 consecutive staging lymphadenectomies had nodal metastases (Stage D1 prostate carcinoma). Seventy-seven of the 82 cases had at least a 5-year follow-up and 50 had at least a 10-year follow-up. Three of these 77 cases had Grade 1 (well-differentiated) metastases, 59 (77%) had Grade 2-3 (moderately differentiated) metastases, and 15 (19%) had Grade 4 (poorly differentiated) metastases (M. D. Anderson Hospital [MDAH] grading system). The patients with moderately differentiated metastases had 5-year and 10-year survival rates of 79% and 34%, respectively, whereas the patients with poorly differentiated metastases had 5-year and 10-year survival rates of 13% and 0%, respectively (P less than 0.0001). This study demonstrates a statistically significant difference between the prognosis of Stage D1 patients with moderately differentiated metastases and Stage D1 patients with poorly differentiated metastases. Consequently, the evaluation of the histologic appearance of Stage D1 metastases may be of clinical importance.
Asunto(s)
Carcinoma/patología , Neoplasias de la Próstata/patología , Carcinoma/mortalidad , Carcinoma/secundario , Estudios de Seguimiento , Humanos , Metástasis Linfática , Masculino , Estadificación de Neoplasias , Pronóstico , Neoplasias de la Próstata/mortalidadRESUMEN
One hundred prostates from 20 to 40 year old men obtained at necropsy were completely sectioned and studied microscopically. Atypical hyperplasia was found in 10 (20%) of 20-29 year old men and in 12 (24%) of 30-40 year old men. The prostates with atypical hyperplasia had similar weights as those without, and the atypical hyperplasia was most common in the lateral lobes of the prostate and near the apex. The atypical hyperplasias were (i) usually mild in degree rather than moderate or severe; (ii) almost equally divided between circumscribed and "infiltrating" lesions; (iii) usually occurred as multiple foci within the same prostate rather than as a single focus of atypical hyperplasia; and (iv) were not associated with inflammation. The finding that atypical hyperplasia is common in men between the ages of 20 and 40 years may be helpful in increasing the understanding of the histopathology of the prostate.